IMW 2019 | MM: AMG 701 BiTE

Yu-Tzu Tai

Dr. Yu-Tzu Tai, PhD of the Dana-Farber Cancer Institute, Boston, MA, speaks on recent research which indicates the success of AMG 701, a new Bi-specific T-cell engager (BiTE) both in monotherapy and combination therapy when tackling tumor cells directly. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Share this video